Giglia-Mari G, Zotter A, Vermeulen W. DNA damage response. Cold Spring Harb Perspect Biol. 2011;3(1):a000745. https://doi.org/10.1101/cshperspect.a000745.

Article  PubMed  PubMed Central  CAS  Google Scholar 

de Laat WL, Jaspers NG, Hoeijmakers JH. Molecular mechanism of nucleotide excision repair. Genes Dev. 1999;13(7):768. https://doi.org/10.1101/gad.13.7.768. – 85.

Article  PubMed  Google Scholar 

Cleaver JE. Defective repair replication of DNA in xeroderma pigmentosum. Nature. 1968;218(5142):652–6. https://doi.org/10.1038/218652a0.

Article  PubMed  CAS  Google Scholar 

Fromme JC, Verdine GL. Base excision repair. Adv Protein Chem. 2004;69:1–41. https://doi.org/10.1016/S0065-3233(04)69001-2.

Article  PubMed  CAS  Google Scholar 

Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. J Med Genet. 1999;36(11):801–18.

PubMed  PubMed Central  CAS  Google Scholar 

San Filippo J, Sung P, Klein H. Mechanism of eukaryotic homologous recombination. Annu Rev Biochem. 2008. https://doi.org/10.1146/annurev.biochem.77.061306.125255. 77:229 – 57.

Article  PubMed  Google Scholar 

Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem. 2008;283(1):1–5. https://doi.org/10.1074/jbc.R700039200.

Article  PubMed  CAS  Google Scholar 

Moore JK, Haber JE. Cell cycle and genetic requirements of two pathways of nonhomologous end-joining repair of double-strand breaks in Saccharomyces cerevisiae. Mol Cell Biol. 1996;16(5):2164–73. https://doi.org/10.1128/MCB.16.5.2164.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78–94. https://doi.org/10.1038/s41568-022-00535-5.

Article  PubMed  CAS  Google Scholar 

Loehrer PJ, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma—a cooperative group-study. J Clin Oncol. 1992;10:1066–73. https://doi.org/10.1200/JCO.1992.10.7.1066.

Article  PubMed  Google Scholar 

von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–77. https://doi.org/10.1200/JCO.2000.18.17.3068.

Article  PubMed  Google Scholar 

Teo MY, Seier K, Ostrovnaya I, Regazzi AM, Kania BE, Moran MM, Cipolla CK, Bluth MJ, Chaim J, Al-Ahmadie H, Snyder A, Carlo MI, Solit DB, Berger MF, Funt S, Wolchok JD, Iyer G, Bajorin DF, Callahan MK, Rosenberg JE. Alterations in DNA damage response and repair genes as potential marker of Clinical Benefit from PD-1/PD-L1 blockade in Advanced Urothelial Cancers. J Clin Oncol. 2018;36(17):1685–94. https://doi.org/10.1200/JCO.2017.75.7740.

Article  PubMed  PubMed Central  CAS  Google Scholar 

n der Heijden MS, Sonpavde G, Powles T, Necchi A, Burotto M, Schenker M, Sade JP, Bamias A, Beuzeboc P, Bedke J, Oldenburg J, Chatta G, Ürün Y, Ye D, He Z, Valderrama BP, Ku JH, Tomita Y, Filian J, Wang L, Purcea D, Patel MY, Nasroulah F, Galsky MD. CheckMate 901 Trial investigators. Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N Engl J Med. 2023;389(19):1778–89. https://doi.org/10.1056/NEJMoa2309863.

Article  PubMed  Google Scholar 

Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR, Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab Vedotin Plus Pembrolizumab in previously untreated Advanced Urothelial Cancer. J Clin Oncol. 2023;41(1):22–31. https://doi.org/10.1200/JCO.22.01643.

Article  PubMed  CAS  Google Scholar 

Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, van der Homet Moreno B. EV-302 Trial investigators. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N Engl J Med. 2024;390(10):875–88. https://doi.org/10.1056/NEJMoa2312117.

Article  PubMed  CAS  Google Scholar 

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, deVere White RW, Sarosdy MF, Wood DP Jr, Raghavan D, Crawford ED. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349(9):859–66. https://doi.org/10.1056/NEJMoa022148.

Article  PubMed  CAS  Google Scholar 

Pfister C, Gravis G, Fléchon A, Soulié M, Guy L, Laguerre B, et al. Randomized phase III trial of dose-dense methotrexate, Vinblastine, Doxorubicin, and cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for patients with muscle-invasive bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial secondary endpoints: Chemotherapy Toxicity and pathological responses. Eur Urol. 2021;79:214–21. https://doi.org/10.1016/j.eururo.2020.08.024.

Article  PubMed  CAS  Google Scholar 

Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder preservation with twice-a-Day Radiation Plus Fluorouracil/Cisplatin or once Daily Radiation Plus Gemcitabine for muscle-invasive bladder Cancer: NRG/RTOG 0712-A randomized phase II trial. J Clin Oncol. 2019;37(1):44–51. https://doi.org/10.1200/JCO.18.00537.

Article  PubMed  CAS  Google Scholar 

Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol. 2014;32(34):3801–9. https://doi.org/10.1200/JCO.2014.57.5548.

Article  PubMed  PubMed Central  Google Scholar 

Zlotta AR, Ballas LK, Niemierko A, Lajkosz K, Kuk C, Miranda G, Drumm M, Mari A, Thio E, Fleshner NE, Kulkarni GS, Jewett MAS, Bristow RG, Catton C, Berlin A, Sridhar SS, Schuckman A, Feldman AS, Wszolek M, Dahl DM, Lee RJ, Saylor PJ, Michaelson MD, Miyamoto DT, Zietman A, Shipley W, Chung P, Daneshmand S, Efstathiou JA. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis. Lancet Oncol. 2023;24(6):669–81. https://doi.org/10.1016/S1470-2045(23)00170-5.

Article  PubMed  Google Scholar 

Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307. https://doi.org/10.1038/nrd1691. – 20.

Article  PubMed  CAS  Google Scholar 

Compe E, Egly JM. TFIIH: when transcription met DNA repair. Nat Rev Mol Cell Biol. 2012;13(6):343–54. https://doi.org/10.1038/nrm3350.

Article  PubMed  CAS  Google Scholar 

Orioli D, Compe E, Nardo T, Mura M, Giraudon C, Botta E, et al. XPD mutations in trichothiodystrophy hamper collagen VI expression and reveal a role of TFIIH in transcription derepression. Hum Mol Genet. 2013;22(6):1061–73. https://doi.org/10.1093/hmg/dds508.

Article  PubMed  CAS  Google Scholar 

Pal SK, Frankel PH, Mortazavi A, Milowsky M, Vaishampayan U, Parikh M, Lyou Y, Weng P, Parikh R, Teply B, Dreicer R, Emamekhoo H, Michaelson D, Hoimes C, Zhang T, Srinivas S, Kim WY, Cui Y, Newman E, Lara PN Jr. Effect of cisplatin and Gemcitabine with or without Berzosertib in patients with Advanced Urothelial Carcinoma: a phase 2 Randomized Clinical Trial. JAMA Oncol. 2021;7(10):1536–43. https://doi.org/10.1001/jamaoncol.2021.3441.

Article  PubMed  Google Scholar 

Karnitz LM, Zou L. Molecular pathways: targeting ATR in cancer therapy. Clin Cancer Res. 2015;21(21):4780–5. https://doi.org/10.1158/1078-0432.CCR-15-0479.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Hall AB, Newsome D, Wang Y, et al. Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970. Oncotarget. 2014;5(14):5674–85. https://doi.org/10.18632/oncotarget.2158.

Article  PubMed  PubMed Central  Google Scholar 

Grivas P, Loriot Y, Morales-Barrera R, Teo MY, Zakharia Y, Feyerabend S, Vogelzang NJ, Grande E, Adra N, Alva A, Necchi A, Rodriguez-Vida A, Gupta S, Josephs DH, Srinivas S, W